Prostate Cancer

Raoul S. Concepcion, MD, FACS, discusses considerations for urologists in this new era.

Mark Emberton, MD, FRCS, professor, Interventional Oncology, Division of Surgery and Interventional Science, University College London, clinical director, Clinical Effectiveness Unit, Royal College of Surgeons of England, discusses the importance of a multidisciplinary approach to the treatment of patients with localized prostate cancer.

Up to 30% of men with prostate cancer could meet criteria for genetic evaluation for hereditary disease. The challenge is separating the mutations that are relevant from those that are not.

Deborah A. Bradley, MD, oncologist, Levine Cancer Institute, discusses next steps for research in nonmetastatic prostate cancer.

James Kearns, MD, assistant professor of medicine, Levine Cancer Institute, discusses adverse events associated with surgery in patients with high-risk prostate cancer.

Earle Burgess, MD, associate professor of medicine, Levine Cancer Institute, Atrium Health, discusses pivotal clinical trials in metastatic castration-sensitive prostate cancer.

Scott T. Tagawa, MD, discusses an emerging treatment modality for patients with progressive metastatic castration-resistant prostate cancer.

Higher survival rates were observed with radical prostatectomy and adjuvant radiotherapy compared with radiotherapy and androgen deprivation therapy in men with locally advanced prostate cancer.

A panel of experts has recommended hypofractionated radiation as an alternative to longer, conventional courses of radiation for men with earlystage prostate cancer who opt for external beam radiation therapy.

Michael J. Morris, MD, medical oncologist, clinical director, Genitourinary Medical Oncology Service, Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses the use of prostate-specific membrane antigen (PSMA)-targeted imaging in patients with metastatic castration-resistant prostate cancer.